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Clinical utility
Standardisationof tumours (ESFT) are diagnosed by EWS–ETS gene translocations. The resulting
fusion proteins play a role in both the initiation and maintenance of these solid aggressive malignant
tumours, suppressing cellular senescence and increasing cell proliferation and survival. EWS–ETS fusion
proteins have altered transcriptional activity, inducing expression of a number of different target genes
including telomerase. Up-regulation of hTERT is most likely responsible for the high levels of telomerase
activity in primary ESFT, although telomerase activity and expression of hTERT are not predictive of
outcome. However levels of telomerase activity in peripheral blood may be useful to monitor response to
some therapeutics. Despite high levels of telomerase activity, telomeres in ESFT are frequently shorter than
those of matched normal cells. Uncertainty about the role that telomerase and regulators of its activity play
in the maintenance of telomere length in normal and cancer cells, and lack of studies examining the
relationship between telomerase activity, regulators of its activity and their clinical signiﬁcance in patient
samples have limited their introduction into clinical practice. Studies in clinical samples using standardised
assays are critical to establish how telomerase and regulators of its activity might best be exploited for
patient beneﬁt.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
1.1. Ewing's sarcoma family of tumours (ESFT)
The Ewing's sarcoma family of tumours (ESFT) include Ewing's
sarcoma, peripheral primitive neuroectodermal tumours (pPNET)
and Askin tumour. These solid tumours share similar histology,
under the light microscope appearing as small round cells with
regular nuclei surrounded by a narrow rim of clear or pale
cytoplasm (Fig. 1). Some tumours contain rosettes suggestive of a
tendency towards neural differentiation, although these tumours
are largely poorly differentiated. Ultrastructurally the tumour cells
are primitive, with scant organelles and cytoplasmic glycogen pools
or aggregates [1,2]. The tumours arise in a number of different
sites, most frequently in the bone (Ewing's sarcoma) or soft tissues
(pPNET or Askin tumour). The ESFT of bone are thought to
originate in the intra-medullary cavity rapidly progressing onto the
cortex to produce a soft tissue component, whereas soft tissue
ESFT often occur adjacent to the bone with no apparent intraoss-
eous component or in isolated soft tissues. There is a peak+44 113 2429886.
ll).
ll rights reserved.incidence of diagnosis in young people between the ages of 10 and
24 years, affecting approximately 0.6 per million total population
with a male to female ratio of 1.5:1. ESFT are not associated with
familial cancer syndromes, although Caucasians are more fre-
quently affected than Afro-Caribbean and Chinese populations [3–5].
The identiﬁcation of non-random chromosome rearrangements
between the EWS gene on chromosome 22q12 and a member of
the ETS gene family is strong evidence for the common histogenesis
of these tumours, and provides a valuable characteristic for their
differential diagnosis from other small round cell tumours of
childhood [6].
Multi-agent chemotherapy, surgery, and radiation therapy have
improved the 5 year progression-free survival (PFS) of newly
diagnosed patients with localised disease to 70%. However, the
5 year PFS for patients who present with pulmonary metastases is
40% and for those with disease in the bone and/or bone marrow is
b20%. Despite aggressive treatment regimens and improved local
control therapy, recurrence and metastasis continue to pose the
most difﬁcult challenge for management and curative treatment of
these solid cancers. Of the patients who relapse only 49–60%
achieve partial or complete remission to second line treatment
[7–10]. These ﬁgures emphasise the urgent need for greater
understanding of the molecular events that contribute to the
development and maintenance of the ESFT malignant phenotype,
to identify both biomarkers to improve selection and stratiﬁcation of
Fig. 1.Molecular characterisation of ESFT. (a) Light microscopy of two ESFT after staining with haematoxylin and eosin, demonstrating small round cell histology. Tumour a. Ewing's
sarcoma within decalciﬁed bone. Tumour b. soft tissue pPNET. (b) G-banding of chromosomes 11 and 22 from an ESFT with the t(11.22)(q24.q12). Arrows identify exchange of
material from chromosome 22q12 to 11q24. (c) RT-PCR for EWS–FLI1 gene rearrangements in two tumours showing type 1 (1) and type 2 (2) fusion transcripts. +c=ampliﬁcation
of RNA from the TC-32 cell line demonstrating the type 1 EWS–FLI1 fusion transcript; RT+ contains reverse transcriptase enzyme and the negative control RT− does not. (d) FISH on
interphase of an ESFT showing presence of t(11.22)(q24.q12). EWS BAC (222M10) labelled green; FLI-1 BAC (428J4) labelled red. Note that the der(11) exhibits a residual red signal
generated by the translocation.
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more effective cancer therapeutics.
2. EWS–ETS translocations and the transformed phenotype
ESFT are one of the few solid tumours for which the underlying
molecular genetic abnormality has been described, that is rearrange-
ment of the EWS gene on chromosome 22q12 with an ETS gene family
member. These rearrangements have not been reported in normal
cells. The most frequent translocation is the t(11;22)(q24;q12) which
is described in 85% of tumours, resulting in the chimeric EWS–FLI1
fusion. Other EWS–ETS fusions have been described in the remaining
15% of tumours (Table 1). These diagnostic translocations can be
identiﬁed by conventional G-banding, although diagnostic accuracy is
often improved using reverse transcriptase polymerase chain reaction
and/or ﬂuorescent in situ hybridisation (FISH) [11–13] (Fig. 1).
The EWS–ETS fusion proteins contain the transactivating domain
of EWS and the DNA binding domain of the corresponding ETS fusion
partner (Table 1). Consistent with the hypothesis that the EWS–ETS
fusions are important for the development and maintenance of the
ESFT malignant phenotype, expression of EWS–FLI1 in a proportion of
NIH3T3 cells increases the ability of these cells to form tumours in soft
agar or in immunocompromised mice [14,15], whereas decreased
expression of EWS–FLI1 in ESFT cells in vitro appears to decrease
proliferation [16–18] and reduce tumour growth and/or metastases in
preclinical mouse models [17,19–22]. More recently EWS–FLI1 has
been shown to suppress cellular senescence [23,24]. The transforming
activity of EWS–ETS fusions has largely been attributed to the altered
transcriptional activity and targets of the EWS–ETS gene fusion
proteins compared to those of the wild-type genes alone [14,25–29].
A number of target genes are differentially induced or repressed
during EWS–FLI1 dependent transformation [6], although the detailed
mechanism of transformation remains elusive. Since no single or
group of gene(s) has yet been identiﬁed that reproduces the ESFT
malignant phenotype it has been suggested that transcriptional
activity may not be the only mechanism of EWS–ETS fusion-induced
transformation. Consistent with this hypothesis, introduction of pointmutations in the FLI1 DNA binding domain (preventing DNA binding)
does not necessarily inhibit the transforming activity of EWS–FLI1
[30]. Furthermore some studies have suggested that the transforming
activity of EWS–FLI1 might be attributed to modulation of RNA
processing [31–33]. These observations are consistent with the
hypothesis that the fusion gene alone is insufﬁcient to cause overt
ESFT, and that accumulation of secondary genetic events is essential
for clinical manifestation of the transformed phenotype.
3. Secondary abnormalities
Although the EWS–ETS fusions are important for the development
andmaintenance of the ESFT malignant phenotype, secondary genetic
abnormalities have been described in over 80% of tumours. Various
numerical and structural aberrations have been identiﬁed, some of
which are reported to be prognostically signiﬁcant. Chromosome gain
is more frequently described than chromosome loss, those patients
presenting with more than 50 chromosomes having a signiﬁcantly
worse over-all survival rate [34]. A more complex karyotype has also
been associated with a worse outcome [34,35]. Although high-ploidy
has been described in a small subset of tumours [36], ESFT are usually
diploid or near triploid [37]. Trisomies of chromosome 8 [38–41] and
12 [39] are frequently described and associated (alone or in
combination) with poor disease course and clinical outcome, although
this has been disputed [34,42]. Several other trisomies including 2, 5,
7, 14 and 21 have been reported, although there is no compelling
evidence that these are of prognostic value. A number of structural
imbalances have also been described, including the unbalanced
translocation t(1;16) [35,43–46], deletions of 1p36 [35,39,44], 9p21
[34,44,47–50] and gain of 1q [34,51,52]. Interestingly, the number of
imbalances is generally reported to be more common in localised than
metastatic tumours [39,42]. However the clinical signiﬁcance of many
of these secondary abnormalities remains unclear, reﬂecting in part
the small number of patients in which they have been systematically
evaluated.
The most frequently described secondary genetic aberrations in
ESFT are deletions of the CDKN2A locus on chromosome 9p, and
Table 1
Non-random EWS gene rearrangements identiﬁed in bone and soft tissue sarcomas
a. Translocation of the EWS gene on chromosome 22q12 with a member of the ETS family of transcription factors is diagnostic of ESFT (shown in bold). Additional rearrangements
of the EWS gene and alternative translocations described in other sarcomas are shown.
b. The EWS breakpoint on chromosome 22q12 is usually constant, but the breakpoint within the partner ETS gene familymember can vary. Themost frequently described abnormality
in ESFT is the t(11;22)(q24;q12) leading to the EWS–FLI1 type 1 gene fusion transcript; this is generated from the ﬁrst seven exons of EWS joined to exons 6–9 of Fli1.
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Although loss of the retinoblastoma gene product pRb is rarely
described in primary ESFT [44,49], loss of the cyclin-dependent kinase
(CDK) inhibitors p16, p21WAF and p27KIP1 (that bind to the CDK–cyclin
D1 complexes preventing inactivation of pRb and consequently
stopping G1/S transition) has been reported. Of these, deletion of
CDKN2A exon 1α (which codes for p16) is the most frequently
described, occurring in between 13 and 39% of primary ESFT
[44,47,49,50,53,54]. Although mutations in p21WAF have not been
described loss of expression is reported in 55–60% of tumours [49,55];
whether this is of prognostic signiﬁcance remains to be seen. Loss or
low expression of the cyclin-dependent kinase inhibitor p27KIP1 has
however been related to poor event-free survival [56]. Aberrations
of p53 have also been described [44,57,58], and although mutations
of p53 are reported in only a small subset of primary ESFT (b10%) in
these patients they are associated with a poor prognosis [48,55,59].
However, most tumours express wild-type p53, high levels of which
in primary tumours appear to be an indicator of poor outcome
[60,61].
4. ESFT signatures and cell of origin
Genome-wide analysis of primary ESFT has identiﬁed tumour
speciﬁc gene signatures that can distinguish ESFT from other bone and
soft tissue cancers [62–66]. It is anticipated that these proﬁles will
elucidate common molecular pathways that are responsible for the
ESFT phenotype [67], and may identify common targets for the
development of novel therapeutics.Recent proﬁles of tumours [68] and model systems of ESFT [63]
suggest that ESFT may arise in as yet poorly deﬁned mesenchymal
progenitor cells. Consistent with this hypothesis, knock-down of
EWS–FLI1 in ESFT cells results in a gene expression proﬁle that more
closely resembles the mesenchymal stem cell than the original ESFT
cell [69]. Furthermore expression of EWS–FLI1 in human bone
marrow-derived mesenchymal progenitor cells induces transforma-
tion to generate cells that grow tumours that resemble ESFT
histologically in nude mice [70,71].
Early studies favour a primitive neural crest cell as the putative cell
of origin, based largely on immature tumour neural phenotype and
the potential of some cells for neural differentiation [72,73]. As these
tumours are predominantly cholinergic [74,75], they may arise from
postganglionic parasympathetic primordial cells which are located
throughout the parasympathetic autonomic nervous system. Thewide
distribution of these pluripotent stem cells is consistent with the
variety of soft tissue and bony locations inwhich ESFT are found. More
recently the expression of EWS–FLI1 in neural crest stem cells has
been shown to disrupt normal neural crest development [76],
providing further support that neural crest stem cells may be the
cells of origin for this aggressive malignant tumour. However
expression of the EWS–ETS fusions can also induce transformation
of ﬁbroblasts [14], haemopoietic cells [77] and cells derived from
primary bone [78], demonstrating that although the transforming
activity of the EWS–ETS fusion may be dependent on cellular context
this is not strictly limited to a primitive mesenchymal or neural cell
milieu. Furthermore the capacity of the EWS–FLI1 fusion to induce a
neurosecretory-phenotype in mesenchymal-derived NIH 3T3 cells
Table 2
The evidence to support the utility of telomerase as a prognostic and/or predictive biomarker in a range of malignancy
Tumour type Pathological
translocation
Telomere maintenance Prognostic/predictive impact
ESFT Yes (EWS–ETS) Telomerase Tumour
Short telomeres=poor prognosis [105]
Detectable telomerase activity=not signiﬁcant [81,156]
Detectable hTERT protein levels=not signiﬁcant [86]
High telomerase activity=not signiﬁcant [157]
Detectable telomerase activity in 12.5% of primary tumours and 100% metastases;
high telomerase activity=poor prognosis [82]
Peripheral blood
High telomerase activity and high hTERT expression in follow-up=poor prognosis [81]
Neuroblastoma No Telomerase Tumour
Short telomeres=good prognosis [158]
High telomerase activity=poor prognosis [152,158–160]
High hTERT and hTR levels=poor prognosis [152]
High WT hTERT levels=poor prognosis [161]
Low hTR levels and low telomerase activity=good prognosis [162]
Detectable telomerase activity at diagnosis or end of treatment=poor prognosis [163]
Nephroblastoma
(Wilm's tumour)
No Telomerase Tumour
Short telomeres=associated with high risk tumours [164]
Detectable telomerase activity=not signiﬁcant [164]
High hTERT mRNA expression=poor prognosis [165,166]
High hTR expression=poor prognosis [165]
Hepatoblastoma No Telomerase Tumour
High hTERT=poor prognosis [167]
High telomerase activity=poor prognosis [167]
Osteosarcoma No Telomerase+ALT (50%) Tumour
Telomerase activity=no correlation with prognosis [168]
High telomerase activity=poor prognosis [82]
Low telomerase activity=increased risk of relapse [157]
Soft tissue sarcomas Variable Telomerase+ALT
(50%) [169]
Tumour
High hTERT=poor prognosis [170]
Alveolar
rhabdomyosarcoma
Yes (PAX-FKHR) Telomerase Tumour
Short telomeres=no correlation with prognosis [171]
Telomerase activity detected=no correlation with prognosis [171]
Embryonal
rhabdomyosarcoma
No Telomerase+ALT
(50%) [171]
Tumour
Long telomeres=no correlation with prognosis [171]
Liposarcoma No Telomerase+ALT (40%) Tumour
Long telomeres=high tumour grade [172]
High telomerase activity=tumour progression/high grade [172,173]
High hTERT=tumour progression/high grade [172,173]
High hTR=poor prognosis [153]
Melanoma No Telomerase Tumour
High telomerase activity=early metastatic spread [174]
High telomerase activity=poor pathological features [175]
Bladder carcinoma No Telomerase Tumour
High hTERT level=worse tumour grade and stage [176,177]
Detectable hTR=no correlation with prognosis [177]
Urine detectable telomerase activity=no correlation with prognosis [178]
Colorectal carcinoma No Telomerase Tumour
High telomerase activity=poor prognosis [179,180]
High hTERT level=poor prognosis [181]
Gastric carcinoma No Telomerase Tumour
High telomerase activity (distal cancers)=poor prognosis [182]
Telomerase activity detected=poor prognosis [183]
High telomerase activity=higher grade [184]
Breast carcinoma No Telomerase Tumour
Telomerase activity=no correlation with prognosis [185,186]
High telomerase activity=poor prognosis [187]
High telomerase activity=recurrence rate [188]
hTERT detected=poor prognosis [189]
High hTERT=poor prognosis [190]
Non small cell lung
carcinoma (NSCLC)
No Telomerase Tumour
Telomerase activity=poor prognosis [191,192]
Telomerase activity and high hTERT expression=poor prognosis [193]
Short telomeres=poor prognosis [194]
Gliomas No Telomerase+ALT
(16–25%) [195,196]
Tumour
High telomerase activity=poor prognosis [197]
Focal hTERT=poor prognosis [198]
hTERT MNS16A genotype=no correlation with prognosis [199]
hTERT MNS16A SS genotype=better prognosis [200]
ALT phenotype=better prognosis [195,196]
Central pNET/medulloblastoma No Telomerase Tumour
High hTERT levels=no correlation with prognosis [201]
Acute promyelocytic
leukaemia (APML)
Yes (APL-RARα) Telomerase PBMC
Short telomeres=poor prognosis [87]
High telomerase activity=poor prognosis [87]
(continued on next page)( )
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Table 2 (continued)
Tumour type Pathological
translocation
Telomere maintenance Prognostic/predictive impact
Chronic myeloid
leukaemia (CML)
Yes (BCR-ABL) Telomerase PBMC
Short telomeres=poor prognostic score [202]
Telomere shortening=poor prognosis (transition to blastic phase) [203]
High telomerase activity=accelerated/blastic phase [204]
BM
High telomerase activity in chronic phase=poor prognosis [205]
Acute leukaemias
(not APML)
No Telomerase PBMC
High telomerase activity=poor prognosis [206]
Telomerase activity=no correlation with remission rate [207]
hTERT level=no correlation with remission rate in childhood leukaemia [208]
Telomerase activity=no correlation with remission rate in adult AML [209]
High telomerase activity=better remission rate [210]
BM
High telomerase activity=poor prognosis in pediatric patients [207]
High hTERT=good prognosis in childhood ALL [208]
Chronic lymphocytic
leukaemia (CLL)
No Telomerase PBMC
Low telomerase activity=good prognosis [211]
BM
Short telomeres=poor prognosis [212]
High telomerase activity=poor prognosis [212]
PBMC: peripheral blood monocytes, BM: bone marrow,WT: wild-type hTERT: human telomerase reverse transcriptase, hTR: human telomerase RNA, ALT: alternative lengthening of
telomeres, ALL: acute lymphoblastic leukaemia.
264 A. Proctor et al. / Biochimica et Biophysica Acta 1792 (2009) 260–274[79] makes the identiﬁcation of the cell in which ESFT arise even more
challenging, since the limited neural phenotype associated with some
ESFT might not reﬂect the cell of origin but rather be a consequence of
the transforming EWS–FLI1 fusion. The cell, or indeed cells, in which
ESFT arise therefore currently remain(s) elusive.
5. Telomerase and regulation of its activity in ESFT
Telomerase activity is up-regulated by the transcriptional activator
EWS–FLI1 [80], the most frequently described primary gene alteration
that characterises ESFT. It is therefore unsurprising that telomerase
activity has been detected in both primary ESFT samples [81–83] and
ESFT cell lines [80,83–85]. The detection of the human telomerase
reverse transcriptase (hTERT) catalytic subunit of telomerase in
primary ESFT by immunohistochemistry is consistent with these
observations [86]. However, neither telomerase activity nor expres-
sion of hTERT has been reported to predict outcome in patients with
ESFT [81,86]. One study has described higher levels of telomerase
activity in metastatic lesions of ESFT compared to levels in tumours at
diagnosis [82], though the proportion of positive primary tumours in
this study was much lower (12%) than that reported in other studies
(70% [83] and 84% [81]). Although this requires further investigation,
increased telomerase activity in metastatic secondary lesions com-
pared to that in tumour at diagnosis would be consistent with the
hypothesis that tumours continually select for incrementally higher
levels of telomerase activity as they proliferate and acquire genetic
changes associated with invasive cancer [87,88].
Although telomerase activity is not prognostic in primary tumour,
in a small group of patients consistently high telomerase activity in
peripheral blood taken during follow-up correlated with a reduced
progression-free survival compared to that in patients where telomer-
ase activity was low or became low after treatment [81]. Telomerase
activity measured in peripheral blood from patients with ESFT may
arise from disseminating ESFT cells. Indeed Ohali et al. [81] reported a
good correlation between telomerase activity and the presence of
disease detected by RT-PCR for EWS–ETS fusion transcripts, suggesting
that telomerase may be a useful marker of minimal residual disease.
However the reduced sensitivity of ESFT cell detection using
telomerase activity (1 ESFT cell in 1×104 normal cells) compared to
that of RT-PCR for EWS–ETS fusions (1 cell in 1×106 normal cells) and
discordance between telomerase activity and RT-PCR for EWS–ETS
fusions in peripheral blood from some patients [81], does not support
this hypothesis. Nevertheless high telomerase activity, arising fromESFTcells inperipheral blood taken frompatients on follow-up,maybe
a useful marker of response and clinical course independent of
minimal disease status. In vitro studies have shown that the
chemotherapeutics doxorubicin [85] and imatinib [89] down-regulate
telomerase activity in ESFT cell lines, consistent with the hypothesis
that changes in telomerase activity and/or factors regulating this
activity may be useful biomarkers of response to therapy during
treatment and follow-up. The imatinib-induced decrease in telomer-
ase activity is associated with induction of cell cycle arrest, although
themechanismof action is unclear [89]. The hypothesis that changes in
telomerase activity within haemopoietic compartments might reﬂect
tumour burden or be a useful biomarker of response measured in
peripheral blood mononuclear cells is not new (Table 2). However
these possibilities require further investigation in prospective quality
controlled clinical trials, with relevant controls to account for the
variability in telomerase activitywithin peripheral bloodmononuclear
cells from non-treated age-matched controls.
Telomerase activity in ESFT cells is most likely increased through
EWS–FLI1 dependent up-regulation of hTERT, either directly [80] or
indirectly through a target gene such as MYC-C which activates the
hTERT promoter [90,91] and is itself up-regulated by EWS–FLI1
[25,92] (Fig. 2). However increased copy number of the genes
encoding components of the telomerase pathway, such as the
regulatory human telomerase RNA (hTR) and hTERT genes located
on chromosomes 3q26.3 and 5p15.33 respectively, might also be
responsible for the up-regulation of telomerase activity in ESFT.
Consistent with this idea trisomy of chromosome 5 has been reported
in 15% [34] and gain of 5p in 20% [65] of primary tumours, although
one study has failed to identify gain of 3q or 5p in 20 primary ESFT
[38]. Chromosomal gains and gene ampliﬁcations involving chromo-
some arms 5p and 3q are among the most frequently described in
human tumours, and increased gene dosage of the telomerase
regulatory genes hTERT and hTR has been described and associated
with clonal evolution in a variety of cancers, suggesting that this
provides a growth advantage for these cells [93].
Tumour microenvironment might also inﬂuence the activity of
telomerase in ESFT, since like most solid tumours the ESFT
microenvironment is heterogeneous with areas of hypoxia reﬂecting
the abnormal vasculature network and high proliferation rate of the
cells [94]. Hypoxia-induced stabilisation of hypoxia-inducible factor-1
(HIF-1) is reported to increase telomerase activity through several
mechanisms including up-regulation [95,96] or alternative splicing
[97] of hTERT mRNA, up-regulation of hTERT protein [96,98] or up-
Fig. 2. Potential sites of telomerase regulation in ESFT. The hTERTgene is regulated by numerous transcription factors acting on the promoter. EWS–ETS fusion transcripts can complex
with CBP/p300 leading to up-regulation of both hTERT transcription and telomerase activity (⁎it is not clear if it has the same effect on hTR). There is also an ETS binding site in the
hTERT promoter which may be the target for some fusion proteins (⁎⁎). Different ETS family members may also confer altered interactions with the hTERT promoter on EWS–ETS
fusions [80], which may include adjacent binding sites like AP-1 although this possibility requires investigation. The up-regulation of MYC-C by the EWS–ETS fusions may also in turn
promote hTERT and hTR transcription through the promoter E-box sites [25,92]. HIF-1 can also act at the hTERT and hTR promoters, relevant in areas of hypoxia within ESFT [94].
Alternative splicing is an important regulatory mechanism for the hTERT gene and all of the major mRNA isoforms are present in ESFT cells in vitro (Proctor, unpublished
observations). The alpha splice variant has a dominant negative action on telomerase [100,232] although it is not clear whether regulation by splicing takes place at the RNA or
protein level (†).
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directly inﬂuences the transcriptional activity of the EWS–ETS protein,
the CREB-binding protein p300 promotes HIF-1 transcriptional
activity [99] and also cooperates with EWS–ETS in the initiation
complex of TERT transcription [80], implying that hypoxia may
inﬂuence telomerase activity in ESFT. Furthermore the alternative
splice variants (wild-type, α-, β-, α-β-) of hTERT are differentially
expressed in ESFT cell lines in hypoxia and normoxia, suggesting that
alternative splicing of the hTERTgenemay regulate telomerase activity
in ESFT cells as described in other systems [100–104] (Fig. 2).
6. Telomere maintenance in ESFT
ESFT are reported to express and utilise telomerase to maintain
telomere length [83]. However despite the presence of functional
telomerase, telomeres in ESFT are frequently shorter than those of
matched normal cells [83,105,106]. Therefore, although telomere
stabilisation is a requisite step in tumorigenesis the shortening of
telomeres must occur at some point in ESFT development. When this
shortening takes place and whether it occurs in telomerase positive or
negative cells is not clear. Since critically shortened telomeres have
been described in precancerous lesions [88,107,108] and in patients
with Fanconi anaemia that have an increased susceptibility to developcancer [109], it seems likely that telomere shortening is an early event
driving the development of ESFT. Therefore the short telomeres may
be a consequence of rapid proliferation prior to activation of
telomerase. In this model ESFT may arise in telomerase negative
cells by generation of the EWS–ETS translocations, which drive
proliferation resulting in the development of shortened telomeres
leading to chromosome instability, crisis, and subsequently activation
of telomerase to stabilise the telomere and suppress cellular
senescence (Fig. 3). Consistent with the idea that EWS–ETS play a
role in the maintenance of the ESFT malignant phenotype through
maintenance of telomere length, EWS–FLI1 is reported to up-regulate
telomerase activity [80] and prevent cellular senescence [23,24]. This
hypothesis is consistent with the concept that chromosomal instabil-
ity underlies the generation of changes in the chromosome and
generation of genomic heterogeneity, to maintain proliferation and
drive development of the malignant phenotype during tumorigenesis.
Of course it may be that ESFT arise in cells that express telomerase but
that this is insufﬁcient to maintain telomere length in the rapidly
dividing transformed cells, resulting in EWS–ETS dependent up-
regulation of telomerase to stabilise the telomere at an albeit
shortened length. Both of these possibilities suggest that telome-
rase-mediated stabilisation of telomeres is not an early event in
tumorigenesis, and are supported by observations that EWS–ETS
Fig. 3. Telomere biology and telomerase in ESFT. ESFT contain EWS–ETS fusions, have shortened telomeres and increased levels of telomerase activity. It is unclear whether telomere
shortening leads to increased genetic instability to facilitate the formation of the EWS–ETS translocation or whether the EWS–ETS fusion is the initiating event that drives cell
proliferation resulting in telomere shortening. What is clear is that the EWS–ETS fusions and factors like hypoxia and MYC-C are important in the reactivation of telomerase, which
along with acquired abnormalities in cell cycle regulators allow ESFT cells to avoid senescence and stabilise the shortened telomeres. Continued cell division in the presence of
shortened telomeres is permissive to the acquisition of further oncogenic changes, which contribute to the development and maintenance of the cancer phenotype.
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environment. Whether the ESFT precursor cell has shortened
telomeres resulting in genetic instability leading to translocation of
the EWS gene, or whether the EWS–ETS translocations arise in
precursor cells inducing genetic instability resulting in shortened
telomeres, up-regulation of telomerase activity and accumulation of
secondary genetic abnormalities remains to be seen. Increased
understanding of the relationship between secondary genetic
changes, genome instability, tumour progression and the identiﬁca-
tion and characterisation of the cell(s) in which ESFT arise will inform
the development of these hypotheses.
Those patients that present with ESFT in which the telomeres are
shorter compared to those with unchanged or longer telomeres are
reported to have a 5-fold increased risk of relapse [105]. Whether
abnormal shortened telomeres and accumulation of G1 cell cycle
checkpoint defects in ESFT predict a worse outcome is not know,
although it is interesting to speculate that together these may
predispose cells to unbalanced chromosome segregation at cell
division and development of a more complex genotype. However,
levels of telomerase activity in ESFT at diagnosis are elevated but do
not correlate with telomere length and are not predictive of outcome
[81,105]. These data might be taken to suggest that telomere length is
not dependent on telomerase activity in ESFT. However it is most
likely that telomerase has a fundamental telomere-dependent role in
the initiation of tumorigenesis (described above), and subsequently
plays both telomere-dependent and -independent roles in the
progression and maintenance of the malignant phenotype [110].
7. Clinical utility; potential, challenges and reporting
Increasing evidence that dysfunctional telomeres play a causal role
in the process of malignant transformation has made them attractive
as potential biomarkers for early cancer diagnosis and prognostica-tion. That abnormally short telomeres are prevalent at the premalig-
nant stage also raises the interesting possibility that avoidance or
reversal of the malignant phenotype by interfering with factors that
regulate telomere length could be a potential strategy for cancer
chemoprevention. Since the majority of tumours appear to rely on
telomerase to maintain telomere length for immortalisation and
genomic stabilisation, this enzyme is an attractive target for the design
of novel cancer therapeutics [111–113]. Recent studies demonstrating
telomere independent tumour-enhancing activities of telomerase
[114] make it even more appealing as a target. Although the role of
telomerase and telomere dynamics in normal and cancer cells is not
fully understood, it is anticipated that increased understanding of
these processes will allow for their more precise exploitation for
therapeutic advantage.
Even though much about telomere biology and the plethora of
proteins that play roles in maintenance of telomere length remain
unclear, several proof of principal studies have demonstrated that
telomere length, telomerase activity and in some cases the potential
regulators of its activity hTR and hTERT may be of predictive and/or
prognostic value (Table 2). The key advantage of these as biomarkers
is that they are features of most cancer cells (including putative cancer
stem cells), and critical for the development and progression of these
malignancies. However uncertainty about the signiﬁcance of telomere
length and of low or transient expression of telomerase and regulators
of its activity in normal biology compared to cancer patho-physiology
has slowed their introduction into clinical practice. This highlights the
importance of investigating these factors in paired tumour and normal
samples, and evaluating the impact of tumour heterogeneity on their
potential clinical signiﬁcance. These studies will beneﬁt from analyses
in speciﬁc cancer and normal cell populations, and an evaluation of
the impact that proliferation and cell cycle-dependent regulation of
telomerase activity will have. The use of in situ assays to detect
telomerase activity [115,116] and hTERT mRNA [117–119], or
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sorting [122–125] to isolate speciﬁc cell populations prior to assays for
telomerase or regulators of its activity will facilitate these studies.
Failure to deﬁne the clinical utility of these markers also reﬂects the
small patient numbers in individual studies and lack of standardisa-
tion of assays and reporting, emphasising the importance of
prospective studies utilising standardised assays. Such studies
demand that an assay is robust, reproducible, sensitive, and speciﬁc
(Fig. 4), and that standardisation is established from sample
collection, transfer and storage in the laboratory, through to analysis
and data reporting.
In this ﬁnal section we have discussed some of the fundamental
practical and technical challenges of evaluating telomere length, hTR,
hTERT and telomerase activity in clinical samples.
Telomere shortening in tumour compared to adjacent non-tumour
or peripheral blood is attractive as a prognostic marker as the assays
are performed on DNA which is relatively stable and readily isolated
from tissues. This may also be informative in different cancer types
(Table 2), regardless of the mechanism of telomere maintenance.
Telomere length is traditionally measured by determination of a mean
telomere restriction fragment (TRF) length. This requires restriction
enzyme digest of genomic DNA (~1 μg) from tumour and a paired
normal tissue, Southern blot and hybridisation to a probe for the
telomeric repeats (TTAGGG)n. This method is most informative when
DNA is extracted from fresh frozen tissue comprising purely tumour or
normal cells, overcoming the heterogeneity of tumours and providing
cancer cell speciﬁc estimations of telomere length and not an average
telomere length from a mix of normal and cancer cells. However
sufﬁcient amounts of this precious resource are not always available,
especially when cancers are diagnosed by small needle biopsies and in
rare cancers such as ESFT. Therefore alternative methods for the
measurement of telomere length have been developed (Table 3). Most
useful has been the development of a quantitative assay utilising the
polymerase chain reaction (PCR), which has the advantage that it canFig. 4. Considerations prior to introduction of assays in clinical trials. Summary of the co
biomarkers such as telomerase in clinical samples.be performed in amounts of DNA (~200 ng) that can be isolated from
small numbers of pure cell populations. This assay is also robust,
quantitative, rapid and amenable to high throughput [126–128].
Most studies of telomere length have focussed on the measure-
ment of average telomere length in tumour compared to normal cells.
However this may not be as informative as analysing telomere length
of individual chromosomes, since it may be that attrition of speciﬁc
chromosomes (and dysfunction of the genes which they carry) will
initiate the malignant process. Single telomere length analysis
(STELA) has identiﬁed large-scale differences in telomere length
throughout development [129], as well as a class of extremely short
telomeres in human cancer cell lines [130]. However, the biological
and clinical signiﬁcance of speciﬁc telomere shortening in both
normal and cancer cells requires further investigation. Currently
STELA has only been developed to analyse telomere length of a limited
number of chromosomes including chromosomes 2p, 11q, 12q, 17p
and the sex chromosomes [129,131], although there is the potential to
develop the technique to examine telomere length in all
chromosomes.
Telomerase is the enzyme, which together with telomere-
binding proteins, appears to be essential for the immortalisation
of most human cancer cells. However the initial expectation that
telomerase activity would be a universal speciﬁc marker of
malignancy has not been realised and its potential clinical utility
remains unresolved.
Telomerase activity is most widely measured in clinical samples
using the PCR based telomerase repeat ampliﬁcation protocol (TRAP)
assay [132], or adaptations of this protocol. The assay measures the
telomerase-dependent addition of (TTAGGG)n repeats to the end of a
synthetic primer with a telomere-like sequence (TS primer). The
extended oligonucleotide products are then ampliﬁed by PCR and
the ampliﬁed DNA band products (6 bp apart) are separated by
polyacrylamide gel electrophoresis and typically visualised by
autoradiography. Semi-quantitative evaluation relative to an internalnsiderations that need to be addressed to evaluate the potential clinical relevance of
Table 3
Summary of the techniques used to determine telomere length and telomerase activity
Measurement Assay Basic protocol Advantages Disadvantages References
Telomere
length
TRF length Digestion of DNA by restriction
enzymes, analysed by Southern
blot. Signal intensity quantiﬁed
by densitometry
Accurate Requires large amounts of DNA (N1 μg). [105,
213–217]Reproducible Time consuming.
No need for specialist equipment. Quantiﬁcation not accurate.
Suitable for analysis of tumour, BM
and PB; requires DNA extraction.
Telomere length is an average of all cells
analysed including any contaminating
normal cells.
Q-FISH Direct hybridisation of a
ﬂuorescent-labelled probe to
telomeric repeats on an intact
metaphase spread
Good correlation with TRF results
obtained by Southern blot.
Expensive equipment needed. [107,120,122,
218–222]
High throughput analysis possible. A high degree of technical expertise
needed.b30 metaphase cells needed for
analysis.
Chromosome speciﬁc telomere
measurements can be obtained
Suitable for analysis of tumour
sections, BM and PB; BM and PB
analysis requires
puriﬁcation of white blood cells.
Flow FISH A combination of FISH and ﬂow
cytometry.
Good correlation with TRF results
obtained by Southern blot.
Not suitable for analysis of solid
tumours.
[122–125]
Measurement of telomere length in
cellular subpopulations possible.
Loss of cells and DNA during processing
and non-speciﬁc binding of the
telomere probe have been reportedAnalysis possible with 1000 cells.
Suitable for analysis of BM and PB
samples; requires puriﬁcation of
white blood cells.
Analysis is rapid (within one day).
Quantitative
PCR
The ratio of telomere repeat copy
number is compared to a single
copy gene copy number.
Good correlation with TRF results
obtained by Southern blot.
Care must be taken when designing
the primers to ensure speciﬁc
ampliﬁcation and avoid primer
dimer generation.
[126–128]
Analysis possible with a 200 ng of DNA.
Simple protocol.
Rapid high throughput samples analysis
is possible.
Suitable for analysis of tumour, BM and
PB; requires DNA extraction.
Tumour speciﬁc telomere length possible
if tumour cells are isolated by laser capture
microdissection.
Single telomere
length analysis
(STELA)
PCR based assay designed for
individual chromosomes
Allows telomere lengths from individual
chromosomes to be measured in detail.
High throughput analysis not possible. [129, 130,
223]
Suitable for analysis of tumour, BM and PB;
requires DNA extraction.
Use for analysis of clinical samples
not well documented.
Telomerase
activity (TA)
Standard
TRAP assay
Telomerase adds 5′TTAGGG3′ repeats
to a synthetic primer, products are
ampliﬁed by PCR, separated by
polyacrylamide gel electrophoresis
and visualised by autoradiography.
TA is quantiﬁed by densitometry,
phosphoimaging or ﬂuoroimaging.
The ‘Gold standard’ method for
measurement of TA.
Quantiﬁcation is not accurate. [132–136]
Suitable for analysis of frozen tumour,
BM, PB, and body ﬂuids including urine
and bile. For BM, PB and ﬂuids white
blood cells must be puriﬁed prior to
protein extraction.
Relatively time consuming.
No need for specialist equipment.
Analysis requires 6 μg protein.
TA is an average of all cells analysed
including any contaminating normal
cells.
ELISA based
TRAP assay
Adaptation to the TRAP assay, an
ELISA replaces the gel
electrophoresis stage.
More simple and quicker than the
standard TRAP assay.
Quantiﬁcation is still post PCR therefore
not accurate.
[121]
Sensitivity and intra-assay variability is
comparable to the standard TRAP assay.
Analysis requires 50 sections of frozen
tumour or 2×105 cells.
Suitable for analysis of frozen tumour,
BM, PB, and body ﬂuids including urine
and bile. For BM, PB and ﬂuids white
blood cells must be puriﬁed prior to
protein extraction
TA is an average of all cells analysed
including any contaminating normal
cells.
Real-time
quantitative
PCR TRAP
Adaptation to the TRAP assay for
real-time PCR by inclusion of either
SYBR green which binds
double-stranded amplicons or speciﬁc
probes in the PCR reaction.
Reduces protocol time. Real-time PCR system needed. [224–230]
More suitable for high throughput analysis. Some studies have reported false
positives due to primer dimer
formation with the use of SYBR
green.
Assay suitable for analysis of small amounts
of material; 1000 cells or approximately
250 ng protein
More accurate quantiﬁcation.
Data has been shown to be comparable to
standard TRAP but with increased sensitivity.
Suitable for analysis of tumour, BM, PB, and
body ﬂuids including urine and bile. For BM,
PB and ﬂuids white blood cells must be
puriﬁed prior to protein extraction.
Tumour speciﬁc telomere length possible if
tumour cells are isolated by laser capture
microdissection.
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Table 3 (continued)
Measurement Assay Basic protocol Advantages Disadvantages References
TRAPeze XL kit
(Millipore)
adapted for
real-time
analysis
The TRAPeze XL is a commercially
available kit for and ELISA based
TRAP assay but has been adapted
for real-time analysis and involves
inclusion of a ﬂuorescent probe
in the PCR reaction.
The kit provides a standard that can be
used in assays therefore allowing
standardised reporting of results.
Real-time PCR system needed [227–231]
Reported to have an increased speciﬁcity
compared to the incorporation of SYBR
green.
It is suggested that an internal control
is used to normalise TA during
ampliﬁcation however it has been
reported that the internal control
reduced rather than improved the
correlation coefﬁcient.
Improved reliability, assay time and
accuracy of quantiﬁcation compared to
the standard TRAP assay.
Suitable for analysis of tumour, BM, PB,
and body ﬂuids including urine and bile.
For BM, PB and ﬂuids white blood cells
must be puriﬁed prior to protein extraction.
Analysis is possible with only 1000 cells or
500 ng protein.
Tumour speciﬁc telomere length possible
if tumour cells are isolated by laser capture
microdissection.
A number of different techniques have been used to determine telomere length and telomerase activity. This table identiﬁes these techniques and details their advantages and
disadvantages including their suitability for the analysis of clinical samples.
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depending on the label used e.g. phosphoimager [133], ﬂuoroima-
ging [134] or in-gel staining with SYBR Green™ [135,136]. Each assay
includes a series of controls to validate the data including a negative
control (pretreatment of the samples with heat or RNase A) and a
positive control cell line. This assay is highly sensitive, reportedly
detecting telomerase activity in as few as 10 immortal cancer cells
[137]. With this sensitivity telomerase activity has been detected in
some normal somatic cells [138–140] and in several benign tumours
[140,141]. Usually telomerase activity is higher in immortalised
cancer cells than in these normal somatic or benign cancer cells.
However to evaluate and compare telomerase activity between
normal and cancer cells a reliable method of quantiﬁcation, with a
common reporting standard is needed. More recently telomerase
activity has been measured using a real-time quantitative TRAP assay
which requires smaller amounts of clinical material, important when
analysing small numbers of isolated tumour, tumour stem cells or
normal cells from valuable clinical material (Table 3). Real-time
TRAP also enables a more accurate quantiﬁcation of telomerase
activity, and with the inclusion of standardised telomerase reference
materials may be useful to deﬁne the threshold of telomerase
activity attributed to non-cancerous cells and so better evaluate
clinical relevance [142].
hTERTand hTR are twomajor components of the active telomerase
complex, and have been investigated as surrogate markers of
telomerase activity. Expression of hTERT mRNA and protein appears
to be more restricted than expression of hTR RNAwhich is detected in
all cell types; a protein product of hTR has not been described. All are
frequently over expressed in tumours compared to normal cells, and
may be prognostic or predictive of outcome in some cancer patients
(Table 2). Furthermore hTERT proﬁles may be predictive of response
to some therapeutics [143,144]. Measurement of these regulators
might therefore predict patient response to a drug, assess efﬁcacy of
treatment ormonitor disease status to predict relapse. hTERT has been
widely described as a major regulator of telomerase activity [145,146],
and a correlation between hTERT and telomerase activity has been
reported in several different cancer types including ESFT [81]. This has
made hTERT the most widely used surrogate marker for telomerase
activity. However, hTERT mRNA has several splice variants some of
which are inactive and competitive inhibitors of hTERT driven
activation of telomerase activity (Fig. 2). These are also expressed in
cells that do not express telomerase activity suggestive of a
telomerase-independent activity [147]. There is increasing evidencethat hTR is also over expressed in tumour compared to normal cells
where it may play a role in telomere maintenance, regulation of
telomerase activity [148–151] and predict prognosis [152]. High levels
of hTR have also been described in tumours that utilise ALT to
maintain telomere length [153], suggesting that hTR, like hTERT, has
telomerase-independent activity. Consequently this may be an
informative biomarker regardless of the mechanism of telomere
maintenance.
As biomarkers hTERT and hTR are attractive as they can be
measured using the high through put sensitive quantitative reverse
transcriptase (RT)-PCR, and may be informative in readily accessible
clinical materials such as washings, brushings, ﬁne needle aspirations,
peripheral blood and urine. Using quantitative RT-PCR the sensitivity
of hTERT detection is 9–10 malignant cells [154]; (Brownhill,
unpublished observations), whereas hTR can be detected in a single
cell (Brownhill, unpublished observations) consistent with its higher
expression levels. However, deﬁning their clinical utility has been
hampered by their expression in normal cells, low copy number per
cell (hTERT) and lack of consensus about their relationship with
telomerase activity and the role they play in tumorigenesis. As with
TRAP assays [155] within a clinical setting, quantitative RT-PCRmay be
useful to determine a threshold of normal expression and so deﬁne
levels relevant to disease status and outcome. Studies in patient
samples have not systematically examined the relationship between
telomerase activity, hTERT and its isoforms and hTR (Fig. 2) and their
clinical signiﬁcance. These studies are critically important to establish
how these factors might best be used to inform management of
patients with cancer.
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